Advicenne signs € 20 million financing agreement with European Investment Bank to support future development

Advicenne (Euronext Paris & Brussels: ADVIC – FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney diseases, announces today that it has signed a loan agreement in for the amount of € 20 million with the European Investment Bank (EIB), the bank of the European Union, within the framework of the Investment Plan for Europe, also known as the Juncker Plan.